Mary Ann Liebert

(Redirected from Gen. Eng. Biotechnol. News)

Mary Ann Liebert, Inc. is a privately held independent publishing company founded by its president, Mary Ann Liebert, in 1980.[2][3] The company publishes peer-reviewed academic journals, books, and trade magazines in the areas of biotechnology, biomedical sciences, medical research, and life sciences; clinical medicine, surgery, and nursing; technology and engineering; environmental science; public health and policy; law, regulation, and education.

Mary Ann Liebert
Founded1980; 44 years ago (1980)
FounderMary Ann Liebert
Country of originUnited States
Headquarters locationLarchmont, New York[1]
DistributionWorldwide
Publication typesAcademic journals, books, and trade magazines
No. of employees100 (2000)[1]
Official websiteLiebertPub.com

The company's headquarters is in New Rochelle, New York.[3][1]

The company has been described as the first to establish a specialty in genetic engineering.[4]

Publications edit

Eschewing traditional market research, the publisher seeks out niche topics overlooked by larger publishers.[1] As of 2000, its portfolio of more than ninety peer-reviewed journals included:[1][5][6][7]

Publications focused on topics outside of the medical field include Westchester Wag, which covers the social scene in Westchester County, New York, and Rinkmagazine, a skating periodical.[1]

History edit

The company's first publication was the Journal of Interferon Research, launched in 1981.[1] Genetic Engineering News was launched the same year, attaining a circulation of 50,000 by 2000.[1] The combined circulation of all titles from the publisher in 2000 was 250,000.[1]

The company's top five publications by revenue as of 2000 were Genetic Engineering News (50,000), Westchester Wag (50,000), Journal of Women's Health and Gender-Based Medicine (5,000), Human Gene Therapy (2,300), and AIDS Research and Human Retrovirus (2,150).[1]

In February 2018, the company launched The CRISPR Journal, a bimonthly journal devoted to research advances and commentary in the field of CRISPR and genome editing.[8]

See also edit

References edit

External links edit